Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186986 | 0.97 | CYP4F2 (0.59) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL31108899 | 0.91 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL3279755 | 0.91 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL186368 | 0.91 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL187113 | 0.91 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL185905 | 0.89 | CYP4F2 (0.68) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL12056074 | 0.88 | CYP4F2 (0.59) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL186940 | 0.86 | CYP4F2 (0.65) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL25936769 | 0.86 | CYP4F2 (0.65) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL31108865 | 0.84 | CYP4F2 (0.63) | CYP4F2CYP4A11HTTPKMTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-10941095-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190263742-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10118881-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9624152-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150344388-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9000041-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8975300-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-7304093-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| EP-1701931-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005068412-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050043278-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | GLAS AMERICAS LLC | 2005-02-24 | — | — | US | disclosed |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344388-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | CYP4F2 1126/4885CYP4A11 19/4885HTT 1438/4885 |
| US-20190263742-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | CYP4F2 1126/4885CYP4A11 19/4885HTT 1438/4885 |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | CYP4F2 1126/4885CYP4A11 19/4885HTT 1438/4885 |
| US-10941095-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | NR1H3, CYP27A1, NR1H2 | CYP4F2 1126/4885CYP4A11 19/4885HTT 1438/4885 |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | CYP4F2 1126/4885CYP4A11 19/4885HTT 1438/4885 |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885HTT 1169/4885 |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885HTT 1169/4885 |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | CYP27A1, NR1H3, PNLIP | CYP4F2 1907/4885CYP4A11 55/4885HTT 1097/4885 |
| US-10118881-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | NR1H3, CYP27A1, NR1H2 | CYP4F2 1126/4885CYP4A11 19/4885HTT 1438/4885 |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | PNLIP, NR1H3, CYP27A1 | CYP4F2 2115/4885CYP4A11 101/4885HTT 915/4885 |
| US-20050043278-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | PNLIP, NR1H3, CYP27A1 | CYP4F2 2115/4885CYP4A11 101/4885HTT 915/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885HTT 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.